Rosetta Aims to Launch New microRNA Test Annually Starting Next Year | GenomeWeb

Rosetta Genomics this week announced updates to its pipeline of microRNA-based diagnostics and therapeutics, stating that it will start commercializing one new assay a year as it moves a treatment for cytomegalovirus (CMV) infection toward the clinic.

Notably, some of these diagnostics will be for indications outside of cancer, which has been the company's main area of interest.

Rosetta was founded in 2000 to develop both miRNA diagnostics and therapeutics, but later shifted its focus to diagnostics, primarily for cancer indications.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.